发明名称 |
Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same |
摘要 |
Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity. Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1. The vaccine composition comprises: a recombinant Env protein as defined above, optionally at least one compound selected from the group consisting of: (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and (2) liposomes and optionally at least one pharmaceutically acceptable vehicle.
|
申请公布号 |
US7063849(B1) |
申请公布日期 |
2006.06.20 |
申请号 |
US20000632806 |
申请日期 |
2000.08.04 |
申请人 |
FONDATION MONDIALE RECHERCHE ET PREVENTION SIDA |
发明人 |
THIBODEAU LISE;LAVALLEE CLAUDE |
分类号 |
A61K39/21;A61K9/00;A61P31/18;C07K14/16 |
主分类号 |
A61K39/21 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|